Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science SummitNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Watch
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Elizabeth Fernandez

Advertisement

Articles by Elizabeth Fernandez

Matthew R. Cooperberg, MD, MPH, of UCSF

Prostate Cancer Test Is Missing Early Disease in Transgender Women

ByElizabeth Fernandez
July 18th 2024

A UCSF-led study alerts transwomen and physicians to interpret standard screening guidelines with caution.

Advertisement

Latest Updated Articles

  • Matthew R. Cooperberg, MD, MPH, of UCSF
    Prostate Cancer Test Is Missing Early Disease in Transgender Women

    July 18th 2024



Advertisement
Advertisement

Trending on OncLive

1

Dr Pant on the Potential Significance of Daraxonrasib for PDAC Management

2

Breast Cancer Buzz at ASCO 2026: De-Escalation Strategies, Targeted Therapies, and More

3

Dr Cummings on the Utility of Adjuvant Immunotherapy Alone in Early-Stage NSCLC

4

Dr Lee on the Optimal Duration of Adjuvant Osimertinib in EGFR+ NSCLC

5

Dr Galsky on the Safety Profile for Enfortumab Vedotin Plus Pembrolizumab in MIBC

  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo
Download on Apple
Download on Google Play

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us